Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors.
adoptive cell therapy
chimeric antigen receptor (CAR) T cells
regional therapies
solid tumors cell therapy
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
13 06 2022
13 06 2022
Historique:
pubmed:
30
4
2022
medline:
18
6
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional delivery of CAR T cells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.
Identifiants
pubmed: 35487216
pii: S1535-6108(22)00168-4
doi: 10.1016/j.ccell.2022.04.006
pmc: PMC9197990
mid: NIHMS1809327
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-574Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA235667
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236615
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests P.S.A. declares research funding from ATARA Biotherapeutics; is a Scientific Advisory Board member and consultant for ATARA Biotherapeutics, Bayer, Carisma Therapeutics, Imugene, ImmPactBio, and Takeda Therapeutics; has patents, receives royalties, and owns intellectual property on mesothelin-targeted CAR and other T cell therapies which have been licensed to ATARA Biotherapeutics; has issued a patented method for detection of cancer cells using viruses; and has pending patent applications on a PD-1 dominant negative receptor, on a wireless pulse-oximetry device, and on an ex vivo malignant pleural effusion culture system. All other authors do not have competing interests to disclose.Memorial Sloan Kettering Cancer Center (MSK) has licensed intellectual property related to mesothelin-targeted CARs and T cell therapies to ATARA Biotherapeutics and has associated financial interests.
Références
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Mol Ther. 2018 Apr 4;26(4):986-995
pubmed: 29503195
Nat Med. 2020 May;26(5):712-719
pubmed: 32341579
Sci Transl Med. 2014 Nov 5;6(261):261ra151
pubmed: 25378643
Clin Cancer Res. 2015 Jul 15;21(14):3149-59
pubmed: 25850950
J Clin Invest. 2016 Aug 1;126(8):3130-44
pubmed: 27454297
Nat Med. 2021 Sep;27(9):1544-1552
pubmed: 34253928
J Immunother Cancer. 2017 Mar 21;5:22
pubmed: 28344808
J Immunother Cancer. 2019 Nov 14;7(1):304
pubmed: 31727131
Nat Biotechnol. 2002 Jan;20(1):70-5
pubmed: 11753365
Cancer Discov. 2021 Nov;11(11):2748-2763
pubmed: 34266984
Nature. 2022 Mar;603(7903):934-941
pubmed: 35130560
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24275-24284
pubmed: 31712432